ISSN: 1837-9664Journal of Cancer
Global reach, higher impact
J Cancer 2018; 9(8):1421-1429. doi:10.7150/jca.23583 This issue Cite
Research Paper
Survival Outcomes for Patients with Surgical and Non-Surgical Treatments in Stages I-III Small-Cell Lung Cancer
1. Institute of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwu Road, Jinan, 250021, P.R. China
2. Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwu Road, Jinan, 250021, P.R. China
3. Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwu Road, Jinan, 250021, P.R. China
Citation:
Che K, Shen H, Qu X, Pang Z, Jiang Y, Liu S, Yang X, Du J. Survival Outcomes for Patients with Surgical and Non-Surgical Treatments in Stages I-III Small-Cell Lung Cancer. J Cancer 2018; 9(8):1421-1429. doi:10.7150/jca.23583. https://www.jcancer.org/v09p1421.htm
Other stylesAbstract
Objectives: Chemotherapy and radiation therapy are the standard treatments for patients with small-cell lung cancer (SCLC). However, recent studies suggest that patients with limited stage (I-III) SCLC may benefit from surgical treatment. This study was performed to evaluate the survival outcomes of surgery for stage I-III SCLC.
Methods: This analysis used data from the Surveillance, Epidemiology, and End Results (SEER) database. All stage I-III (excluding N3 and Nx) SCLC patients received a diagnosis between 2004 and 2014. Overall survival (OS) and lung cancer-specific survival (LCSS) were determined by Kaplan-Meier analysis and compared using the log-rank test. A Cox proportional hazard model identified relevant survival variables.
Results: A total of 4,780 histologically confirmed patients were identified from the SEER database, comprising 1,018 patients (21.3%) with stage I disease; 295 (6.2%) with stage II; and 3,467 (72.5%) with stage III disease. Among all of the patients, 520 had been treated with surgery, the majority (n = 344; 66.2%) of whom had stage I disease. The hazard ratio (HR) for OS and LCSS, in patients who underwent surgery, according to stage were as follows: OS, 0.369 and LCSS, 0.335 in stage I; OS, 0.549 and LCSS, 0.506 in stage II; and OS, 0.477 and LCSS, 0.456 in stage III (all p < 0.001). Patients who underwent surgery had significantly better OS, and lobectomy was associated with the best outcome.
Conclusions: Surgical resection was associated with significantly improved OS outcomes and should be considered in the management of stage I-III SCLC.
Keywords: Small-cell lung cancer, surgical resection, lobectomy, postoperative radiation therapy, SEER
Citation styles
APA
Che, K., Shen, H., Qu, X., Pang, Z., Jiang, Y., Liu, S., Yang, X., Du, J. (2018). Survival Outcomes for Patients with Surgical and Non-Surgical Treatments in Stages I-III Small-Cell Lung Cancer. Journal of Cancer, 9(8), 1421-1429. https://doi.org/10.7150/jca.23583.
ACS
Che, K.; Shen, H.; Qu, X.; Pang, Z.; Jiang, Y.; Liu, S.; Yang, X.; Du, J. Survival Outcomes for Patients with Surgical and Non-Surgical Treatments in Stages I-III Small-Cell Lung Cancer. J. Cancer 2018, 9 (8), 1421-1429. DOI: 10.7150/jca.23583.
NLM
Che K, Shen H, Qu X, Pang Z, Jiang Y, Liu S, Yang X, Du J. Survival Outcomes for Patients with Surgical and Non-Surgical Treatments in Stages I-III Small-Cell Lung Cancer. J Cancer 2018; 9(8):1421-1429. doi:10.7150/jca.23583. https://www.jcancer.org/v09p1421.htm
CSE
Che K, Shen H, Qu X, Pang Z, Jiang Y, Liu S, Yang X, Du J. 2018. Survival Outcomes for Patients with Surgical and Non-Surgical Treatments in Stages I-III Small-Cell Lung Cancer. J Cancer. 9(8):1421-1429.
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.